By Ilan Zipkin
Science Editor

Despite missing the primary end point in its first three true Phase III studies of pleconaril in two different viral indications, ViroPharma Inc. believes it has learned enough about conducting clinical trials with the small molecule to demonstrate a significant treatment effect in subsequent Phase III studies.